الفهرس 
Pharmaceutical Study on selected oral antiviral drug for treatment of hepatitis C in Egypt
Table of ContentsOnly 14 pages are availabe for public view
 |  | from | 168 |  |  |
| | | from | 168 | | |
Abstract
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV)
that until recently did not have effective treatments. A new class of oral
antiviral drugs called direct-acting antivirals has, for the first time, provided
an opportunity for widespread scale-up of curative treatment. These oral
medications have been proven to be safe and effective in clearing hepatitis C
from the body within 12 weeks of treatment.
Daclatasvir is a direct-acting antiviral agent used to treat the hepatitis C
virus. Daclatasvir has a bitter taste and poor solubility in water and ethanol at
neutral pH. The drug product is manufactured by a standard manufacturing
process. In-process controls include weight variation, friability,
disintegration time, tablet weight and hardness during tablet compression
and weight gain during film coating.
The formulation technique plays an important role in overcoming the
shortcoming of poorly water-soluble drugs and enhancing patient
compliance. Oral disintegrating tablets offer several advantages over
conventional tablets with reference to their stability, administration without
water, accurate dosing, and easy manufacturing. Their simple administration
within the population especially for paediatric, geriatric, or any people
persons makes them a popular dosage form. They have preferable taste,
enhanced stability, superior bioavailability, greater efficacy, allow for
variable dosing and are more cost-effective and provide a rapid onset of
action.